Article Text

AB0064 Progranulin Antibodies (PGRN-ABS) in Rheumatoid Arthritis More Frequent than in Psoriatic Arthritis
  1. G. Assmann1,
  2. S. Zinke2,
  3. M. Gerling1,
  4. M. Pfreundschuh1,
  5. L. Thurner1,
  6. K. Preuss1
  1. 1Rheumatology and Oncology, University Medical School of Saarland, Homburg
  2. 2Rheumatology, Center Berlin Lichtenberg, Berlin, Germany


Background Until recently, most research on progranulin (PGRN) had been foccussed on its role in neurodegenerative diseases as frontotemporal demetia. However, we discovered antibodies against PGRN in a protein array-based screening of plasma from various different rheumatic diseases (1,2). Furthermore, PGRN-Abs have been proved to have neutralizing effect on PGRN plasma levels; PGRN itself showed antiinflammatory effects by its high-affinity to the TNFa receptor 1 and 2 causing a direct inhibition of the TNFa receptors.

Objectives To evaluate the prevalence of PGRN-Abs in sera of patients with rheumatoid arthritis compared to psoriatic arthritis patients and healthy controls

Methods PGRN-Abs were determined in sera of 201 patients of RA, 260 patients of PsA, and 97 healthy controls. The ELISA detecting PGRN-Abs were applied as previously described (2). The prevalence of PGRN-Abs in sera of RA were compared to PsA and healthy controls. Subgroup analyses has stratifyed the RA cohort according to gender, age, seropositivity of rheumatoid factor (RF) and ACPA, erosive course of disease, duration of disease, and the occurrence of anti-TNF treatment failure. The statistics was performed with the Mann-Whithney U test evaluating the differences between RA, PsA and healthy controls; the using the χ2 test differences between the different RA subgroups were investigated. A p-value of <0.5 was considered significant.

Results PGRN-Abs was detected in 32.6% of the RA cohort with significant higher prevalence compared to PsA (19.2, p=0.014) and healthy controls (1.03, p=0.001). Among the RA subgroups patients on age elder than 60 years (versus younger than 60) and patients with disease duration longer than 5 years (versus shorter than 5 years) showed significantly more frequent PGRN-Abs in their sera.

Conclusions Here we present the first study evaluating the PGRN-Abs in sera of patients with RA. Longer duration of disease seems to favor the occurrence of PGRN-Abs. PGRN-Abs could been detected significantly more frequent in RA than in PsA.


  1. Thurner L & Pfreundschuh M et al, PGRN in autoimmune diseases, J Autoimmunity, 2012

  2. Thurner L & Assmann G et al, PGRN in PsA, Arth Res Th, 2013

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.5925

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.